Evidence map›Paper›PMID 41057718›Full record

ArticleNeurology and therapy2025

The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.

John M Kane, Ofer Agid, David J Castle, Leslie Citrome, Andrea Fagiolini, Taishiro Kishimoto, Carlos A Larrauri, Stefan Leucht, Jose M Rubio, Martha Sajatovic and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John M KaneDepartment of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA. JKane2@northwell.edu.ORCID http://orcid.org/0000-0002-2628-9442
Ofer AgidDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
David J CastleTasmanian Department of Health, Tasmanian Centre for Mental Health Service Innovation, Hobart, TAS, Australia.
Leslie CitromeDepartment of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.
Andrea FagioliniUniversity of Siena, Siena, Italy.
Taishiro KishimotoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Carlos A LarrauriHarvard T. H. Chan School of Public Health, Boston, MA, USA.
Stefan LeuchtDepartment of Psychiatry and Psychotherapy, Technical University of Munich, Klinikum rechts der Isar, TUM School of Medicine and Health, Munich, Germany.
Jose M RubioDepartment of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Martha SajatovicUniversity Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Nina SchoolerDepartment of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Christoph U CorrellDepartment of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntipsychotic medications are effective for people living with schizophrenia, but long-term treatment adherence remains challenging, leading to relapses and poor outcomes. Long-acting injectable antipsychotics (LAIs) may improve adherence and reduce relapses compared with oral antipsychotics. Barriers to the use of LAIs exist, yet practical recommendations to overcome them are lacking. Therefore, an expert consensus panel was formed to develop key recommendations using a modified Delphi panel method.

methodsThe panel chair and Interactive Forums, Inc., conducted a narrative literature review of English-language articles published in the 10 years before 02/02/2024. Panelists rated, discussed, and re-rated proposed statements during 2 online premeetings and 2 virtual group meetings in 2024. Consensus was defined as ≥ 75% agreement.

resultsThe consensus panel initially included 9 experts and was expanded to 12, representing 6 countries and diverse psychiatric and lived experiences. In the first round, 31 recommendations were developed, with a high level of agreement; these were refined to 26 statements in the second round. Recommendations covered: (1) overcoming barriers to LAI initiation and use for the treatment of people with schizophrenia, and (2) procedures for initiation and switching, monitoring, and maintenance of LAIs for people with schizophrenia. The panel recommended that healthcare professionals (HCPs) consider LAIs proactively and initiate them early after a confirmed schizophrenia diagnosis. The importance of continued treatment with LAIs and their role in assessing nonadherence and treatment resistance were also highlighted. Further, the panel recommended that HCPs evaluate any personal biases about LAIs and engage in training/education to support goal setting and shared decision-making with patients and caregivers. Guidance on switching between antipsychotic formulations and maintaining treatment was also provided.

conclusionsThis expert consensus panel provided recommendations to guide HCPs on how to overcome barriers to LAI use and to implement, monitor, and maintain LAIs as routine schizophrenia treatment.

Indexed as

Expert consensusLong-acting injectable antipsychoticsSchizophrenia

Identifiers

PMID41057718
PMCPMC12623523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.